Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus

BMC Medicine

Melanie J Davies³  Kamlesh Khunti¹  Ram Kela²  Kaustubh Nisal² 

[1] Department of Health Sciences, University of Leicester, 22-28 Princess Road West, Leicester LE1 6TP, UK;Department of Diabetes and Endocrinology, University Hospitals of Leicester NHS Trust, Leicester Royal infirmary, Infirmary Square, Leicester LE1 5WW, UK;Diabetes Department, Department of Cardiovascular Sciences, University of Leicester, Leicester General Hospital, Gwendolen Road, Leicester, LE5 4WP, UK

关键词: patient satisfaction;    head to head comparison;    incretins;    DPP-4 inhibitors;    GLP-1 agonists;    GLP-1 analogues;   

Others  :  857273
DOI  :  10.1186/1741-7015-10-152

 received in 2012-03-28, accepted in 2012-11-30,  发布年份 2012

【 摘 要 】

Type 2 diabetes mellitus is widely prevalent and is often coexistent with obesity. Many of the available treatment options have side effects such as weight gain which often affect patient's willingness to continue the treatment. Effective weight loss, lack of significant hypoglycaemia, and favourable cardiometabolic profile make Incretin based therapies an attractive treatment option for type 2 diabetes. Incretin based therapies are available as either incretin mimetics (also called GLP-1 agonists) or incretin enhancers (DPP-4 inhibitors). Although agents in both these classes of incretin based therapy are effective through a common GLP-1 pathway, there are many differences amongst them including the route of administration, frequency of administration, effects on body weight, extent of glycaemic improvement. There are several trials evaluating these individual incretin based agents either as monotherapy or in combination with other anti-diabetic agents, however very few have looked into direct comparison amongst the agents in these two classes. This review is aimed to look at important mechanistic differences between incretin mimetics and enhancers through direct comparison trials and impact of these differences on biochemical, metabolic and patient satisfaction parameters.

【 授权许可】

   
2012 Nisal et al; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Whiting DR, Guariguata L, Weil C, Shaw J: IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011, 94:311-321.
• [2]Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, Farzadfar F, Riley LM, Ezzati M: National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011, 377:557-567.
• [3]National Obesity Observatory: National obesity observatory data. [http://www.noo.org.uk] webcite 2011.
• [4]Daousi C, Casson IF, Gill GV, MacFarlane IA, Wilding JP, Pinkney JH: Prevalence of obesity in type 2 diabetes in secondary care: association with cardiovascular risk factors. Postgrad Med J 2006, 82:280-284.
• [5]Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group Lancet 1998, 352:837-853.
• [6]Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G: Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006, 355:2427-2443.
• [7]Ross SA, Dzida G, Vora J, Khunti K, Kaiser M, Ligthelm RJ: Impact of weight gain on outcomes in type 2 diabetes. Curr Med Res Opin 2011, 27:1431-1438.
• [8]Jacobson AM: Impact of improved glycemic control on quality of life in patients with diabetes. Endocr Pract 2004, 10:502-508.
• [9]Blonde L, Montanya E: Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. Diabetes Obes Metab 2012, 14(Suppl 2):20-32.
• [10]Nauck MA: Incretin-based therapies for type 2 diabetes mellitus: properties, functions, and clinical implications. Am J Med 2011, 124:S3-18.
• [11]Madsbad S, Krarup T, Deacon CF, Holst JJ: Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Curr Opin Clin Nutr Metab Care 2008, 11:491-499.
• [12]Baggio LL, Drucker DJ: Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2157.
• [13]Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
• [14]Drucker DJ: Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26:2929-2940.
• [15]Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824-830.
• [16]Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK Holst JJ: Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001, 86:3717-3723.
• [17]Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ: Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 2001, 50:609-613.
• [18]Kjems LL, Holst JJ, Volund A, Madsbad S: The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003, 52:380-386.
• [19]Bagger JI, Knop FK, Lund A, Vestergaard H, Holst JJ, Vilsboll T: Impaired regulation of the incretin effect in patients with type 2 diabetes. J Clin Endocrinol Metab 2011, 96:737-745.
• [20]Vollmer K, Holst JJ, Baller B, Ellrichmann M, Nauck MA, Schmidt WE, Meier JJ: Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance. Diabetes 2008, 57:678-687.
• [21]Nauck MA, Vardarli I, Deacon CF, Holst JJ, Meier JJ: Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? Diabetologia 2011, 54:10-18.
• [22]Hildebrandt M, Reutter W, Arck P, Rose M, Klapp BF: A guardian angel: the involvement of dipeptidyl peptidase IV in psychoneuroendocrine function, nutrition and immune defence. Clin Sci (Lond) 2000, 99:93-104.
• [23]Kieffer TJ, McIntosh CH, Pederson RA: Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
• [24]Vilsboll T, Agerso H, Krarup T, Holst JJ: Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J Clin Endocrinol Metab 2003, 88:220-224.
• [25]Hendry J: FDA approves exenatide. DOC News 2011, 2005:1-6.
• [26]Eng J, Kleinman WA, Singh L, Singh G, Raufman JP: Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992, 267:7402-7405.
• [27]Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M: The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45:195-202.
• [28]Drucker DJ, Buse JB, Taylor K, Kendall DM, Trautmann M, Zhuang D, Porter L, DURATION-1 Study Group: Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250.
• [29]Januvia [prescribing information] Whitehouse Station, NJ: Merck & Co., Inc; 2010.
• [30]Drucker DJ, Nauck MA: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
• [31]DeFronzo RA, Okerson T, Viswanathan P, Guan X, Holcombe JH, MacConell L: Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008, 24:2943-2952.
• [32]Berg JK, Shenouda SK, Heilmann CR, Gray AL, Holcombe JH: Effects of exenatide twice daily versus sitagliptin on 24-hour glucose, glucoregulatory, and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab 2011, 13:982-989.
• [33]Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, Thomsen AB, Søndergaard RE, Davies M, 1860-LIRA-DPP-4 Study Group: Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447-1456.
• [34]Pratley R, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S Garber A, Thomsen AB, Hartvig H, Davies M, 1860-LIRA-DPP-4 Study Group: One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011, 65:397-407.
• [35]Bergenstal RM, Wysham C, MacConell L, Malloy J, Walsh B, Yan P, Wilhelm K, Malone J, Porter LE, DURATION-2 Study Group: Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376:431-439.
• [36]Lilly Newsroom 2011.
• [37]Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, Gonzalez JG, Chan M, Wolka AM, Boardman MK, DURATION-4 Study Group: Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012, 35:252-258.
• [38]Bergenstal R, Forti A, Chiasson J, Woloschak M, Boldrin M, Leiter L, Balena R: Once weekly taspoglutide, a human GLP-1 analog, is superior to sitagliptin in improving glycemic control and weight loss in patients with type 2 diabetes (T2D): results from the T-emerge 4 trial. Diabetes 2010, 59(Suppl 1):58-OR.
• [39]Nordqvist C: Experimental diabetes drug taspoglutide late-stage trials suspended. [http://www.medicalnewstoday.com/articles/200893.php] webciteMedical News Today 2011.
• [40]Monnier L, Lapinski H, Colette C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003, 26:881-885.
• [41]Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, Zychma M, Blonde L, LEAD-6 Study Group: Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47.
• [42]Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B: Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011, 13:348-356.
• [43]Marre M, Shaw J, Brandle M, Bebakar WM, Kamaruddin NA, Zdravkovic M, Le Thi TD, Colagiuri S, LEAD-1 SU study group: Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009, 26:268-278.
• [44]Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, Zdravkovic M, Düring M, Matthews DR, LEAD-2 Study Group: Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009, 32:84-90.
• [45]Russell-Jones D, Vaag A, Schmitz O, Sethi BK, Lalic N, Antic S, Zdravkovic M, Ravn GM, Simó R: Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009, 52:2046-2055.
• [46]Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P Hale PM, Zdravkovic M, Blonde L, LEAD-4 Study Investigators: Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009, 32:224-1230.
• [47]Okerson T, Yan P, Stonehouse A, Brodows R: Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens 2010, 23:34-339.
• [48]Neumiller JJ: Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) 2009, 49(Suppl 1):S16-S29.
• [49]Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ: Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care 2007, 30:890-895.
• [50]Lovshin JA, Drucker DJ: Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 2009, 5:262-269.
• [51]Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, Gonzalez JG, Chan M, Wolka AM, Boardman MK, DURATION-4 Study Group: Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012, 35:252-258.
• [52]Anderson SL, Trujillo JM: Association of pancreatitis with glucagon-like peptide-1 agonist use. Ann Pharmacother 2010, 44:904-909.
• [53]Tatarkiewicz K, Smith PA, Sablan EJ, Polizzi CJ, Aumann DE, Villescaz C, Hargrove DM, Gedulin BR, Lu MG, Adams L, Whisenant T, Roy D, Parkes DG: Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents. Am J Physiol Endocrinol Metab 2010, 299:E1076-E1086.
• [54]Engel SS, Williams-Herman DE, Golm GT, Clay RJ, Machotka SV, Kaufman KD, Goldstein BJ: Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis. Int J Clin Pract 2010, 64:984-990.
• [55]Drucker DJ, Sherman SI, Bergenstal RM, Buse JB: The safety of incretin-based therapies--review of the scientific evidence. J Clin Endocrinol Metab 2011, 96:2027-2031.
• [56]Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, Braun DK, Noel RA, Seeger JD: A cohort study of acute pancreatitis in relation to exenatide use. Diabetes Obes Metab 2011, 13:559-566.
• [57]Garg R, Chen W, Pendergrass M: Acute pancreatitis in type 2 diabetes treated with exenatide or sitagliptin: a retrospective observational pharmacy claims analysis. Diabetes Care 2010, 33:2349-2354.
• [58]Bjerre KL, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ, Gotfredsen C, Egerod FL, Hegelund AC, Jacobsen H, Jacobsen SD, Moses AC, Mølck AM, Nielsen HS, Nowak J, Solberg H, Thi TD, Zdravkovic M, Moerch U: Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010, 151:1473-1486.
• [59]Parks M, Rosebraugh C: Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy. N Engl J Med 2010, 362:774-777.
• [60]Rossi MC, Nicolucci A: Liraglutide in type 2 diabetes: from pharmacological development to clinical practice. Acta Biomed 2009, 80:93-101.
• [61]Fonseca VA: Ongoing clinical trials evaluating the cardiovascular safety and efficacy of therapeutic approaches to diabetes mellitus. Am J Cardiol 2011, 108:52B-58B.
• [62]Peyrot M, Rubin RR: How does treatment satisfaction work?: modeling determinants of treatment satisfaction and preference. Diabetes Care 2009, 32:1411-1417.
• [63]Nicolucci A, Cucinotta D, Squatrito S, Lapolla A, Musacchio N, Leotta S, Bulotta A, Nicoziani P, Coronel G, QuoLITy Study Group: Clinical and socio-economic correlates of quality of life and treatment satisfaction in patients with type 2 diabetes. Nutr Metab Cardiovasc Dis 2009, 19:45-53.
• [64]Bradley C, Speight J: Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diabetes Metab Res Rev 2002, 18(Suppl 3):S64-S69.
• [65]Davies M, Pratley R, Hammer M, Thomsen AB, Cuddihy R: Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin. Diabet Med 2011, 28:333-337.
• [66]Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, Rungby J, Landau BR, Schmitz O: One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004, 53:1187-1194.